Japan records surprise trade deficit in July as exports weaken further
SAN DIEGO—Cibus, Inc. (NASDAQ:CBUS) Director Gerhard Prante recently sold a portion of his holdings in the company. According to a Form 4 filing with the Securities and Exchange Commission, Prante sold 1,150 shares of Class A Common Stock on February 19, 2025, at a price of $2.58 per share, amounting to a total transaction value of $2,967. The sale comes as the stock trades near its 52-week low of $2.17, having declined over 87% in the past year, according to InvestingPro data.
Following this sale, Prante now directly owns 12,307 shares of Cibus. The transaction was executed automatically under a Rule 10b5-1 trading plan that Prante adopted on August 16, 2024. This type of plan allows insiders to set up a predetermined schedule for buying or selling stock, helping to avoid potential conflicts of interest.
Cibus, Inc., headquartered in San Diego, operates in the agriculture chemicals sector, focusing on innovative solutions in the industry. With a market capitalization of approximately $78 million, the company continues to engage in activities aimed at enhancing its market presence and expanding its product offerings. InvestingPro analysis suggests the stock is currently undervalued, with the company scheduled to report earnings on February 28, 2025. Subscribers can access 15 additional ProTips and a comprehensive Pro Research Report for deeper insights into CBUS’s financial health and growth prospects.
In other recent news, Cibus has announced a direct stock offering aimed at raising approximately $22.6 million to fund its ongoing projects. The offering involves the sale of about 9 million shares at $2.50 per share, with key participants including existing investors and CEO Rory Riggs. Canaccord Genuity analysts responded by lowering Cibus’s stock target from $20 to $18, though they maintained a Buy rating. In a separate development, Jefferies reduced its price target for Cibus from $8 to $5, while maintaining a Hold rating, highlighting the company’s strategic focus on expanding acreage and achieving free cash flow breakeven.
Additionally, Cibus disclosed a new base salary of $320,000 for executive Carlo Broos, effective immediately. This update was part of a recent SEC filing, though details on previous compensation or additional incentives were not provided. The company continues to focus on enhancing its gene-editing technology, with an emphasis on soybean platform development and potential European Union approval. These developments underscore Cibus’s commitment to advancing its research and development initiatives in the agriculture sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.